Neurocrine Biosciences (NASDAQ:NBIX) Now Covered by Stifel Nicolaus

Analysts at Stifel Nicolaus started coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research note issued to investors on Tuesday, August 7th, Marketbeat.com reports. The firm set a “buy” rating and a $137.00 price target on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 11.43% from the company’s current price.

Other research analysts also recently issued reports about the stock. Barclays set a $100.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Friday, June 8th. BidaskClub downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 8th. Oppenheimer set a $120.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Monday, May 14th. Cowen restated a “buy” rating and set a $100.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, May 7th. Finally, Bank of America raised their price objective on shares of Neurocrine Biosciences from $101.00 to $102.00 and gave the company a “buy” rating in a research report on Tuesday, May 1st. Seventeen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $119.25.

Shares of NASDAQ:NBIX traded up $0.85 during trading on Tuesday, reaching $122.95. 352,100 shares of the stock traded hands, compared to its average volume of 768,846. Neurocrine Biosciences has a 52-week low of $51.42 and a 52-week high of $123.32. The company has a quick ratio of 9.19, a current ratio of 9.19 and a debt-to-equity ratio of 1.00. The stock has a market cap of $10.91 billion, a price-to-earnings ratio of -75.90, a PEG ratio of 34.33 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Tuesday, July 31st. The company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.11. Neurocrine Biosciences had a negative net margin of 16.07% and a negative return on equity of 14.22%. The firm had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $84.11 million. During the same quarter in the prior year, the company posted ($0.68) earnings per share. The business’s revenue for the quarter was up 1428.4% on a year-over-year basis. sell-side analysts anticipate that Neurocrine Biosciences will post 0.17 earnings per share for the current year.

In other news, insider Dimitri E. Grigoriadis sold 86,963 shares of the business’s stock in a transaction dated Thursday, June 14th. The shares were sold at an average price of $99.48, for a total value of $8,651,079.24. Following the completion of the sale, the insider now owns 146,905 shares in the company, valued at approximately $14,614,109.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Stephen A. Sherwin sold 10,000 shares of the business’s stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $98.44, for a total transaction of $984,400.00. Following the completion of the sale, the director now owns 47,548 shares of the company’s stock, valued at approximately $4,680,625.12. The disclosure for this sale can be found here. Over the last three months, insiders sold 157,985 shares of company stock valued at $16,071,499. 4.30% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in NBIX. Frontier Capital Management Co. LLC grew its position in Neurocrine Biosciences by 587.3% during the 1st quarter. Frontier Capital Management Co. LLC now owns 826,272 shares of the company’s stock worth $68,523,000 after purchasing an additional 706,047 shares during the last quarter. Artisan Partners Limited Partnership grew its position in Neurocrine Biosciences by 50.3% during the 1st quarter. Artisan Partners Limited Partnership now owns 1,966,109 shares of the company’s stock worth $163,049,000 after purchasing an additional 657,712 shares during the last quarter. Victory Capital Management Inc. grew its position in Neurocrine Biosciences by 86,203.0% during the 1st quarter. Victory Capital Management Inc. now owns 569,600 shares of the company’s stock worth $47,237,000 after purchasing an additional 568,940 shares during the last quarter. Braun Stacey Associates Inc. purchased a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at $14,333,000. Finally, BlackRock Inc. boosted its holdings in shares of Neurocrine Biosciences by 2.8% in the 1st quarter. BlackRock Inc. now owns 4,908,495 shares of the company’s stock valued at $407,061,000 after acquiring an additional 132,749 shares during the last quarter.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Read More: Market Capitalization – What it Means for Investors

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply